ATE531808T1 - Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna - Google Patents
Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dnaInfo
- Publication number
- ATE531808T1 ATE531808T1 AT07000486T AT07000486T ATE531808T1 AT E531808 T1 ATE531808 T1 AT E531808T1 AT 07000486 T AT07000486 T AT 07000486T AT 07000486 T AT07000486 T AT 07000486T AT E531808 T1 ATE531808 T1 AT E531808T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- recombinant cells
- dna
- triplex dna
- vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000012223 nuclear import Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000010839 reverse transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15838799P | 1999-10-12 | 1999-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531808T1 true ATE531808T1 (de) | 2011-11-15 |
Family
ID=22567880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00969534T ATE351916T1 (de) | 1999-10-12 | 2000-10-10 | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
| AT07000486T ATE531808T1 (de) | 1999-10-12 | 2000-10-10 | Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00969534T ATE351916T1 (de) | 1999-10-12 | 2000-10-10 | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8093042B2 (de) |
| EP (2) | EP1224314B1 (de) |
| JP (1) | JP4436024B2 (de) |
| CN (2) | CN101363029B (de) |
| AT (2) | ATE351916T1 (de) |
| AU (2) | AU784910B2 (de) |
| CA (1) | CA2382832C (de) |
| CY (2) | CY1106513T1 (de) |
| DE (1) | DE60033045T2 (de) |
| DK (2) | DK1792997T3 (de) |
| ES (2) | ES2377721T3 (de) |
| HK (1) | HK1050210B (de) |
| IL (3) | IL148900A0 (de) |
| PT (2) | PT1224314E (de) |
| WO (1) | WO2001027304A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| ATE449858T1 (de) | 1999-10-11 | 2009-12-15 | Pasteur Institut | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen |
| ATE351916T1 (de) | 1999-10-12 | 2007-02-15 | Pasteur Institut | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| EP1412493B1 (de) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen |
| EP1438075A4 (de) | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| US8222029B2 (en) * | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| EP1748067A1 (de) | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren |
| ES2423518T3 (es) | 2006-12-22 | 2013-09-20 | Institut Pasteur | Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada |
| EP2150618B1 (de) | 2007-05-04 | 2017-10-11 | University Health Network | Il-12-immuntherapie gegen krebs |
| EP2385107B1 (de) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria |
| EP2666477A1 (de) | 2012-05-23 | 2013-11-27 | Theravectys | Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor |
| WO2012069657A1 (en) | 2010-11-26 | 2012-05-31 | Institut Pasteur | Identification of a human gyrovirus and applications. |
| ES2651922T3 (es) | 2011-11-08 | 2018-01-30 | Institut Pasteur | Polipéptidos de afinidad elevada para MAST2 y usos de los mismos |
| WO2013083753A2 (en) | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
| WO2014016383A2 (en) | 2012-07-25 | 2014-01-30 | Theravectys | Glycoproteins for pseudotyping lentivectors |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| ES2747951T3 (es) * | 2013-10-24 | 2020-03-12 | Ospedale San Raffaele Srl | Método |
| EP3031923A1 (de) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis |
| EP3256578B8 (de) | 2015-02-13 | 2020-04-01 | INSERM - Institut National de la Santé et de la Recherche Médicale | Polypeptide zur entwicklung chimärer integraseproteine und ihre verwendung bei der gentherapie |
| JP7110096B2 (ja) | 2015-11-24 | 2022-08-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | レトロウイルス産生のための一時的トランスフェクション法 |
| EP3211003A1 (de) | 2016-02-24 | 2017-08-30 | Institut Pasteur | T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon |
| EP3443001B1 (de) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | Regulierte bioschaltkreissysteme |
| CA3021572A1 (en) | 2016-04-20 | 2017-10-26 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
| SG11201901540UA (en) * | 2016-06-22 | 2019-04-29 | Univ Yale | Mechanism based quality control for botanical medicine |
| EP3357504A1 (de) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung |
| EP3357506A1 (de) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt |
| EP3592853A1 (de) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Unterdrückung von schmerzen durch geneditierung |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3697452A4 (de) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | Lentivirale vektoren zur verabreichung von pklr zur behandlung von pyruvatkinasemangel |
| BR112020020841A2 (pt) | 2018-04-11 | 2021-01-19 | Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus | Composições e métodos para transplante de célulastronco |
| CN112262214A (zh) | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| CA3096293A1 (en) | 2018-04-27 | 2019-10-31 | Rocket Pharmaceuticals, Ltd. | Gene therapy for cns degeneration |
| WO2019226650A1 (en) | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020106992A1 (en) | 2018-11-21 | 2020-05-28 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| US20240122978A1 (en) | 2019-10-16 | 2024-04-18 | Umoja Biopharma, Inc. | Retroviral vector for univeral receptor therapy |
| CN117120085A (zh) | 2020-07-15 | 2023-11-24 | 巴斯德研究所 | Sars-cov-2免疫原性组合物、疫苗和方法 |
| WO2022015955A1 (en) | 2020-07-16 | 2022-01-20 | Umoja Biopharma, Inc. | Gated adapter targeting receptor |
| EP4185600A4 (de) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Verbesserte virusähnliche partikel und verfahren zur verwendung davon zur abgabe an zellen |
| JP2023538519A (ja) | 2020-08-07 | 2023-09-08 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療 |
| WO2022058621A1 (en) | 2020-09-21 | 2022-03-24 | Theravectys | High throughput methods and products for sars-cov-2 sero-neutralization assay |
| EP3984548A1 (de) | 2020-10-16 | 2022-04-20 | Institut Pasteur | Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren |
| CA3199588A1 (en) | 2020-11-20 | 2022-05-27 | Andrew Scharenberg | Vector system for delivery of multiple polynucleotides and uses thereof |
| US20250319173A1 (en) | 2021-03-12 | 2025-10-16 | Institut Pasteur | Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host |
| EP4448729A1 (de) | 2021-12-17 | 2024-10-23 | Umoja Biopharma, Inc. | Zytotoxische angeborene lymphoidzelle und verwendungen davon |
| US20250382586A1 (en) | 2022-05-17 | 2025-12-18 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
| CN115358393B (zh) * | 2022-09-13 | 2025-12-02 | 大连大学 | 一种基于相互作用力的dna三链体编码优化方法 |
| US20260097108A1 (en) | 2022-10-21 | 2026-04-09 | Institut Pasteur | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host |
| TW202434621A (zh) | 2022-11-04 | 2024-09-01 | 美商優莫佳生物製藥有限公司 | 多核苷酸構築體及相關病毒載體及方法 |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JP2000506727A (ja) * | 1996-03-05 | 2000-06-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン |
| CA2286819A1 (en) | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| FR2777909B1 (fr) * | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US7622300B2 (en) | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
| GB9825524D0 (en) * | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| ATE449858T1 (de) * | 1999-10-11 | 2009-12-15 | Pasteur Institut | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen |
| ATE351916T1 (de) | 1999-10-12 | 2007-02-15 | Pasteur Institut | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
| US20030194392A1 (en) | 2002-04-10 | 2003-10-16 | Pierre Charneau | Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US8158413B2 (en) | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| US8222029B2 (en) | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
-
2000
- 2000-10-10 AT AT00969534T patent/ATE351916T1/de active
- 2000-10-10 ES ES07000486T patent/ES2377721T3/es not_active Expired - Lifetime
- 2000-10-10 EP EP00969534A patent/EP1224314B1/de not_active Expired - Lifetime
- 2000-10-10 JP JP2001530507A patent/JP4436024B2/ja not_active Expired - Lifetime
- 2000-10-10 CA CA2382832A patent/CA2382832C/en not_active Expired - Lifetime
- 2000-10-10 DK DK07000486.6T patent/DK1792997T3/da active
- 2000-10-10 PT PT00969534T patent/PT1224314E/pt unknown
- 2000-10-10 DE DE60033045T patent/DE60033045T2/de not_active Expired - Lifetime
- 2000-10-10 DK DK00969534T patent/DK1224314T3/da active
- 2000-10-10 WO PCT/EP2000/010418 patent/WO2001027304A2/en not_active Ceased
- 2000-10-10 PT PT07000486T patent/PT1792997E/pt unknown
- 2000-10-10 HK HK03100625.0A patent/HK1050210B/en not_active IP Right Cessation
- 2000-10-10 CN CN200810213831.1A patent/CN101363029B/zh not_active Expired - Lifetime
- 2000-10-10 AU AU79217/00A patent/AU784910B2/en not_active Expired
- 2000-10-10 CN CNB00814205XA patent/CN100425702C/zh not_active Expired - Lifetime
- 2000-10-10 IL IL14890000A patent/IL148900A0/xx unknown
- 2000-10-10 ES ES00969534T patent/ES2280250T3/es not_active Expired - Lifetime
- 2000-10-10 EP EP07000486A patent/EP1792997B1/de not_active Expired - Lifetime
- 2000-10-10 AT AT07000486T patent/ATE531808T1/de active
-
2002
- 2002-03-26 IL IL148900A patent/IL148900A/en active IP Right Grant
-
2005
- 2005-12-01 US US11/291,390 patent/US8093042B2/en not_active Expired - Fee Related
-
2006
- 2006-10-26 AU AU2006233199A patent/AU2006233199B2/en not_active Expired
-
2007
- 2007-04-13 CY CY20071100518T patent/CY1106513T1/el unknown
-
2009
- 2009-04-07 IL IL198076A patent/IL198076A/en active IP Right Grant
-
2011
- 2011-11-21 US US13/301,204 patent/US8512994B2/en not_active Expired - Fee Related
- 2011-11-21 US US13/301,147 patent/US8512993B2/en not_active Expired - Fee Related
-
2012
- 2012-01-23 CY CY20121100075T patent/CY1112430T1/el unknown
-
2013
- 2013-07-15 US US13/942,180 patent/US9238824B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 US US14/613,657 patent/US10407695B2/en not_active Expired - Fee Related
-
2018
- 2018-07-24 US US16/044,462 patent/US20190119699A1/en not_active Abandoned
- 2018-07-24 US US16/044,451 patent/US20180346928A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE531808T1 (de) | Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna | |
| JP2020100622A5 (de) | ||
| WO2004022716A3 (en) | Recombinatant mutants of rhabdovirus and methods of use thereof | |
| NO20015587L (no) | Ekspresjon og eksport av interferon-<alfa> proteiner som Fc fusjonsproteiner | |
| WO2002014358A3 (en) | Novel secreted proteins and their uses | |
| ATE318896T1 (de) | Rekombinante rna-replikase von hepatitis-c-virus | |
| WO2000053788A3 (en) | Compositions and methods for recombinant adeno-associated virus production | |
| PT2302063T (pt) | Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo | |
| ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| WO2002008277A3 (en) | Nucleic acids, vectors, host cells, polypeptides, and uses thereof | |
| ATE475713T1 (de) | Trans-lentivirales vektor system | |
| WO2004005467A3 (en) | Expression of human interferon in transgenic chloroplasts | |
| ATE447038T1 (de) | Schweineadenovirus vektor | |
| ATE365807T1 (de) | Hepatitis b virus vektoren für gentherapie | |
| FI885296A0 (fi) | Rekombinant hiv-2 polypeptid. | |
| DE69318716D1 (de) | Anti-Katze Immundefiziensvirus (FIV) Impfstoffe | |
| FR2600079B1 (fr) | Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus | |
| FR2607518B1 (fr) | Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus | |
| WO2002012475A3 (en) | C1q-related factor, homologous polypeptides and therapeutic uses thereof | |
| WO2002016578A3 (en) | Secreted proteins and methods of using same | |
| WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
| RU2346044C2 (ru) | ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum | |
| Patience | Gamma-herpes virus DNA and methods of use | |
| WO2000053789A3 (de) | Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen | |
| WO2002068464A3 (de) | Fusionsprotein zum blocken des hiv nef-proteins |